바이오프론테라(BFRI) 2026년 2분기 실적 발표 회의: 매출 33% 증가, 총이익률 80% 달성

핵심 요약

• 2026년 2분기 제품 매출은 아멜루즈(Ameluz) 판매량이 약 30% 증가하고 2025년 4분기 가격 인상이 반영되면서 전년 동기 대비 32.9% 증가한 1,200만 달러를 기록했습니다.
• 총이익률은 매출의 25%~35% 수준이었던 이전가격(transfer pricing) 방식에서 직불 아멜루즈 원가 및 순매출액의 12% 어른아웃(earn-out) 지급 방식으로 전환된 데 힘입어 기존 71%에서 약 80%로 개선되었습니다.
• 조정 EBITDA는 마이너스 510만 달러에서 마이너스 20만 달러로 개선되어, 전통적 비수기임에도 불구하고 바이오프론테라(Biofrontera)가 손익분기점에 근접했습니다.
• 미국 국제무역위원회(ITC) 명령에 따라 바이오프론테라는 현재의 로도LED XL(RhodoLED XL)을 미국 내로 수입하거나 판매할 수 없으며, 해당 기기용 아멜루즈 판매도 제한됩니다. 다만 설치 기반의 대부분을 차지하는 기존 BF-로도LED(BF-RhodoLED)는 영향을 받지 않습니다.
• 미국 식품의약국(FDA)은 표재성 기저세포암에 대한 아멜루즈의 처방약 유저피법(PDUFA) 목표 기한을 2026년 9월 28일로 설정했습니다. 승인될 경우 경영진은 2027년 1분기에 본격적인 출시가 이루어질 것으로 예상하고 있습니다.
• 2026년 6월 30일 기준 현금 보유액은 470만 달러였습니다. 재무제표에 계속기업 관련 한정/주의 사항(going-concern qualification)이 유지되고 있지만, 경영진은 2026년 현금흐름 손익분기점 달성을 목표로 계속 추진하고 있습니다.

주요 재무 실적

2026년 상반기 매출은 25.4% 증가한 2,210만 달러를 기록했습니다. 총이익률은 67%에서 80%로 상승했으며, 순손실은 950만 달러(주당 1.05달러)에서 540만 달러(주당 0.44달러)로 줄어들었습니다. 조정 EBITDA는 마이너스 950만 달러에서 마이너스 370만 달러로 개선되었습니다.

상반기 영업 현금 유출액은 전년 동기 720만 달러에서 170만 달러로 감소했습니다. 2026년 6월 30일 기준 현금 및 현금성 자산은 470만 달러, 총부채는 1,810만 달러, 자본총계는 600만 달러였습니다. 회사의 유일한 미상환 채무는 2027년 11월 만기 예정인 460만 달러 규모의 전환사채뿐이었습니다.

사업 및 영업 성과

아멜루즈의 판매량 증가가 주요 매출 동인이었습니다. 바이오프론테라는 2분기 동안 33,300튜브를 판매했으나, 경영진은 ITC 관련 규제가 시행되기 전에 앞당겨 이루어진 선구매 물량이 포함되어 있다고 밝혔습니다.

상반기 주문 건수는 전년 동기 대비 18.6% 증가했으며, 주문당 평균 튜브 수도 10% 늘어났습니다. 2025년 4분기 가격 인상 전에 선구매했던 대형 고객 중 81% 이상이 2026년 상반기에 재주문했습니다. 이들 고객 대상 아멜루즈 판매량은 41% 증가했습니다.

바이오프론테라는 상반기 동안 66개의 신규 거래처를 확보하여 전년 동기의 69개와 비슷한 수준을 보였습니다. 내근 영업(Inside sales)을 통해 침투율이 낮은 소형 거래처에서 약 1,070튜브, 공석 상태였던 지역 커버리지를 통해 추가로 920튜브의 판매실적을 올렸습니다.

회사는 2분기에 로도LED XL 16대와 기존 로도LED 5대를 포함해 총 21대의 광선 치료 기기(램프)를 공급했습니다. 이에 따라 누적 설치 기반은 약 740곳의 병·의원에 걸쳐 약 801대에 달했습니다.

경영진 전망

경영진은 ITC 명령 효력 발생 전에 고객들이 아멜루즈를 선구매하면서 발생한 시기적 변동이 바이오프론테라의 2026년 연간 매출 목표를 바꾸지는 않을 것으로 예상한다고 전했습니다. 컨퍼런스 콜에서 수치화된 매출 목표는 제시되지 않았습니다.

바이오프론테라는 2026년 현금흐름 손익분기점 달성을 위한 노력을 계속하고 있습니다. 회사는 아멜루즈 매출 성장과 크세피(XEPI) 매각에 따른 추가 100만 달러의 마일스톤 수령, 그리고 필요시 운전자금 신용한도(credit line) 또는 유사한 금융 수단을 통해 유동성을 지원할 계획입니다.

표재성 기저세포암 적응증과 관련해, FDA는 적응증 추가 신청(sNDA)을 받아들였으며 PDUFA 목표일을 2026년 9월 28일로 지정했습니다. 승인이 이뤄질 경우, 바이오프론테라는 기존의 램프 장비, 피부과 거래처, 영업 인력을 활용해 2026년 4분기에 초기 고객 접근을 시작하고 2027년 1분기에 본격적인 출시를 진행할 예정입니다.

회사는 또한 광선각화증 적응증 대상을 사지, 목, 체간(몸통)으로 확대하고 치료 영역을 최대 240제곱센티미터까지 확장하기 위해 2026년 3분기 말경 적응증 추가 신청(sNDA)을 제출할 계획입니다. 경영진은 2027년 3분기에 FDA 승인을 받을 수 있을 것으로 예상합니다.

바이오프론테라는 아멜루즈 투여군이 58%, 위약(vehicle) 대조군이 37%의 염증성 병변 감소를 보인 임상 2b상 연구 결과를 바탕으로 여드름 임상 프로그램의 다음 단계를 검토하고 있습니다. 향후 임상 개발은 가용 자금 조달 여부에 달려 있습니다.

리스크 및 주시할 항목

ITC는 로도LED XL의 일부 부품이 선 제약(Sun Pharmaceutical)의 특허 2건을 침해했다고 판정했습니다. 이에 따라 7월 7일부터 제한적 수입금지 및 영업정지 명령이 발효되어 바이오프론테라는 현재의 XL 램프 수입 및 판매가 금지되었으며, 해당 기기 사용 목적의 아멜루즈 판매도 제한되었습니다.

이 제재는 경영진이 설치 기반의 상당수를 차지한다고 밝힌 기존 BF-로도LED에는 영향을 미치지 않습니다. 바이오프론테라는 경미한 경첩(hinge) 부품 변경을 포함한 수정된 XL 램프를 개발하고 있습니다. 경영진에 따르면 이 수정 사항은 FDA 관련 CBE-30 단계를 통과했으나, 이것이 ITC 명령 대상에서 제외되는지에 대해서는 아직 미국 국경당국의 확인을 기다리는 중입니다.

바이오프론테라는 1분기에 약 50만 달러의 시정(remediation) 추정 비용을 계상했으며, 경영진은 이 추정치에 변동이 없다고 밝혔습니다. 회사는 또한 연방순회항소법원에 ITC 판정에 항소할 권리를 유지하고 있지만, 상업화 계획이 항소 성공 여부에 의존하지는 않는다고 말했습니다.

유동성은 여전히 경색되어 있습니다. 손익분기점 달성을 향한 진전에도 불구하고, 바이오프론테라는 재무제표에 계속기업 유의 사항을 포함했으며 비용을 통제하는 동시에 매출 성장을 지속적으로 이끌어내야만 합니다.

애널리스트 Q&A 하이라이트

경영진은 표재성 기저세포암 치료제 출시를 위한 준비가 주로 마케팅 자료 확정, FDA 사전 승인 확보, 영업 인력 교육, 보험 수가 및 환급(reimbursement) 전략 완료로 구성된다고 설명했습니다. 해당 적응증에는 회사의 기존 상업화 인프라가 활용될 예정입니다.

수정된 로도LED XL과 관련하여, 경영진은 경첩 변경이 제품 성능이나 의사들의 램프 사용 방식에 실질적인 차이를 유발하지 않을 것이라고 말했습니다. 수정된 기기가 남아 있는 국경 심사 절차를 통과한 후, 현재 XL 기기를 보유한 병원에 대한 교체 조치가 계획되어 있습니다.

경영진은 또한 의원급 병원이 ITC 명령 발효 전에 구매한 아멜루즈 재고를 이미 소유하고 있는 램프와 함께 사용할 수 있다고 명확히 밝혔습니다. 그러나 바이오프론테라는 명령이 발효된 이후에는 특허 침해에 해당하는 로도LED XL과 함께 사용할 목적의 추가 아멜루즈를 판매할 수 없습니다.

실적 발표 컨퍼런스 콜 전문

전체 실적 발표 컨퍼런스 콜 녹취록

경영진 발표

Operator

Welcome to the Biofrontera Second Quarter 2026 Financial Results and Business Update Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Ben Shamsian with Lytham Partners Investor Relations.

Please go ahead.

Behnam Shamsian

Good morning and welcome to Biofrontera Inc.'s Second Quarter 2026 Financial Results and Business Update Conference Call. Please note that certain information discussed during today's call by management is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that Biofrontera's management will be making forward-looking statements and that actual results may differ materially from those stated or implied by these forward-looking statements due to the risks and uncertainties associated with the company's business.

The forward-looking statements on today's call include statements regarding the company's full year 2026 revenue goals, the anticipated effects of the International Trade Commission orders and the company's remediation plan, the company's liquidity and the ability to continue as a going concern, the outcome of pending proceedings and the potential approval and launch of new indications for Ameluz. All risks and uncertainties are detailed and are qualified by the cautionary statements contained in Biofrontera's press release and SEC filings, including the company's quarterly reports on Form 10-Q for the quarter ended June 30, 2026, and the company's annual report on the Form 10-K for the year ended December 31, 2025.

Also, this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast. Biofrontera undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as required by law. During today's call, there will be references to certain non-GAAP financial measures. Biofrontera believes these measures provide useful information for investors, yet should not be considered as a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP.

A reconciliation of non-GAAP to GAAP results is included in the press release issued today and is available on the company's website at www.biofrontera-us.com under the Investor Relations section. Please note management will be referencing adjusted EBITDA, a non-GAAP financial measure defined as net loss excluding interest expense, net income taxes, depreciation, and amortization, and certain other non-recurring or non-cash items, including changes in fair value of warrant liabilities, panel remediation expense, and the related inventory write-down and stock-based compensation.

With that said, I would now like to turn the call over to Hermann Luebbert, CEO, Chairman, and Founder of Biofrontera. Hermann, please proceed.

Hermann Lubbert

Yes, thank you, Ben. And thank you to everyone joining us this morning. The second quarter of 2026 was the strongest operating Q2, and the first half year was the strongest H1 in the company's history as a standalone U.S. business. Net product revenue grew 33% to $12 million. Gross margin reached approximately 80% compared to approximately 71% a year ago. And adjusted EBITDA came to $200,000 of breakeven against a loss of $5.1 million in Q2 of last year. These strong results in Q2, which for us is traditionally a weaker quarter, are not just one quarter out of the ordinary. They reflect the build-up of a commercial organization that is executing along with the expense discipline across the entire organization.

We are seeing the pace of reorders from our physician accounts accelerate, which reflects the strength of underlying demand generation. George and Fred will take you through the details in a moment. The results also further reflect the strategic transaction we completed in October 2025, which gave Biofrontera full ownership and control of all U.S. rights, approvals, and patents for the Ameluz and RhodoLED portfolio, and replaced a transfer pricing model of 25% to 35% of revenue with a 12% earn-out on net sales.

Before diving into the business, I want to address the International Trade Commission matter because I expect it is on your minds. On May 6, the Commission issued its final determination finding a violation of Section 337 with respect to two Sun Pharmaceutical patents covering certain components of our RhodoLED XL lamp. In their decision, the Commission contradicted the conclusion of the U.S. Patent Office's Trial and Appeal Board, which, in agreement with our belief, had previously found every challenged claim of one of the patents unpatentable. The Commission issued a limited exclusion order and cease and desist orders which took effect on July 7.

We can no longer import or sell the current RhodoLED XL lamp in the United States. And we are restricted from selling Ameluz for use with the RhodoLED XL. Three things you should understand about the scope of this. First, this affects the XL lamp. It does not in any way affect the original BF-RhodoLED lamp, which represents the substantial majority of our installed lamp base. Physicians using those lamps are unaffected and Ameluz sales to accounts with the BF-RhodoLED lamp continue normally. Second, we have a remediation plan designed to allow selling a modified version of our XL lamp that is outside the scope of both Sun Pharmaceutical patents.

We recorded approximately $500,000 in the first quarter as our best estimate of the remediation cost, and that estimate has not changed. Because the substantial majority of our installed lamp base is unaffected, and we expect to get approval for providing a modified version of the RhodoLED XL that is outside the patent space, we expect the exclusion order to affect the timing of orders rather than total demand. Third and finally, we are not finished contesting this. We retain the right to appeal the Commission's determination to the Federal Circuit. I will not speculate on how those proceedings will resolve or when. What I will tell you is that while pursuing every avenue available to us, our commercial plan does not depend on winning any of them.

Our commercial success will be because of our continued dedication to doctors and patients, as well as investment in developing Ameluz and PDT to be used in more indications. Now let me turn to the clinical pipeline, because it is the clearest picture of how this company will grow in 2027 and beyond. First, superficial basal cell carcinoma. The FDA accepted filing of our supplemental New Drug Application for Ameluz PDT for the treatment of superficial basal cell carcinoma with a PDUFA target date of September 28, 2026. If approved, Ameluz will be the first PDT in the United States approved for the treatment of cancerous skin tumors, and we expect a full launch in Q1 of 2027 with initial outreach to customers during Q4 of 2026.

That launch would go directly into our existing installed base of BF-RhodoLED lamps and our existing dermatology call points. The commercial infrastructure is already in place. Second,actinic keratosis on the extremities, neck, and trunk. Earlier this year, we announced positive and statistically significant top-line Phase III results, with the study meeting its primary endpoint. This data supports our plan to file a supplemental NDA around the end of the third quarter of 2026 to expand the Ameluz label beyond AKs on the face and scalp to a treatment field of up to 240 square centimeters. We anticipate FDA approval in Q3 2027.

With approximately 58 million American adults having at least 1 AK lesion, extending treatment to the extremities, neck, and trunk, and the larger area, meaningfully expands the addressable use of every lamp already in the field. Third, moderate to severe acne and beyond. Our Phase 2B study showed a 58% reduction in inflammatory lesions with Ameluz compared to 37% with vehicle, and 86% of patients said they would choose PDT treatment again. We are currently in the process of prioritizing and designing our next phase of clinical development, aiming at expanding the addressable market for our products, and acne will be an important part of this discussion. We'll keep you updated as these plans will evolve.

Taken together, sBCC expected to launch in the first quarter of 2027, relevant AK label extensions anticipated in Q3 2027, and an acne program advancing towards Phase III. All of these grow revenue through the same installed lamp and customer base and the same sales force we have already built and paid for. That is the growth model for 2027 and beyond. More approved uses flowing through infrastructure that is already in place.

I would now like to turn the call over to George Jones, our Chief Commercial Officer. George?

George Jones

Thank you, Hermann, and good morning, everyone. We delivered product revenues of $12 million in the second quarter, an increase of approximately 33% year-over-year. The increase was driven by approximately 30% growth in Ameluz unit volume, together with the price increase we implemented in the fourth quarter of 2025. Looking at unit volume, in the second quarter of 2026, we sold 33,300 tubes of Ameluz. This is compared to approximately 25,300 tubes in the second quarter of 2025. The volume growth in the quarter included the impact of order timing from certain customers in anticipation of the ITC-related supply restrictions Hermann described.

The timing of this is good because customers tend to move through Ameluz faster when they have inventory on the shelf, and it sets us up for a strong fourth quarter. Importantly, since the substantial majority of our installed lamp base is unaffected by the exclusion order, we do not expect this shift to impact our full year 2026 revenue goals. Turning to the RhodoLED lamp placements, in Q2 2026, we placed 21 lamps, including 16 XL lamps and 5 RhodoLED lamps. This increased our installed base to approximately 801 lamps across approximately 740 physician offices.

Turning to sales execution, we are seeing significant traction across all aspects of our business. During the first half of 2026, our order count was up 18.6% versus the first half of 2025. And the average tubes per order was up 10%. We have also been tracking our largest customers that made large purchases prior to the price increase in Q4 of 2025. Over 81% of those customers placed additional orders during the first half of 2026. And for those that did reorder, their Ameluz volume was up 41%. This is important because it indicates our sales efforts are working and our customers are increasing their Ameluz PDT throughput within their practice.

I also want to highlight our new account growth. In the first half of 2026, we added 66 new accounts versus 69 new accounts during the first half of 2025. A slight dip is likely due to the focus on current XL customers in May and June prior to the ITC orders coming effective. Lastly, I want to follow up on our last call and draw attention to our inside sales efforts. And those efforts have continued to bear fruit, generating approximately 1,070 tubes of Ameluz from whitespace in smaller accounts, as well as another 920 tubes from covering vacant territories in the first half of 2026.

The first half of 2026 has given me great optimism regarding our commercial strategy and the way our team has delivered. This enhanced execution plus our clinical programs, including the near-term sBCC approval and launch, upcoming label expansion for AKs on the extremities, neck, and trunk, and the advancement of our acne program give us multiple paths and great opportunities for continued growth.

With that, I'll turn the call over to Fred Leffler, our Chief Financial Officer. Fred?

Eugene Leffler

Thank you, George, and good morning, everyone. I'll walk through our results for the second quarter and first half of the year ended June 30, 2026. All comparisons are to the same prior period unless otherwise noted. A full reconciliation of GAAP and non-GAAP measures is included in the press release issued earlier today and available on our website. With that, revenues for the second quarter were $12 million compared to $9 million in the second quarter of 2025. That is an increase of 32.9%. As George described, unit volume grew approximately 30% with the balance of the growth coming from the price increase that was completed in the fourth quarter of 2025.

For the first half of the year, revenues were $22.1 million, up 25.4% from $17.6 million in 2025. Cost of revenue for the quarter was $2.4 million compared to $2.6 million, producing gross profit of $9.6 million and a gross profit margin of about 80%, compared to approximately 71% in the prior year quarter. That's an expansion of roughly 920 basis points. For the first half, gross margin was also 80% against a gross profit margin of 67% in the first half of 2025. The improvement was driven principally by the transition from the prior transfer pricing agreements to a cost structure comprising of Ameluz direct cost plus the 12% earn-out on net revenue.

That structure is contractual and durable, and we will see it continue. Selling, general, and administrative expenses for the quarter were $9.7 million compared to $10.6 million in 2025 that we took over following the strategic transaction. I would note that the litigation-related legal spend is tied to the pace of active matters and can vary quarter to quarter. For the first half, SG&A was $20.7 million compared to $19.3 million, an increase of $1.4 million. This was driven primarily by investment, lower turnover in the commercial organization, and the new manufacturing and regulatory functions I just mentioned. And it was partially offset by lower litigation-related legal fees.

Research and development expenses were $0.4 million for the quarter compared to $0.9 million in 2025 and $1.3 million for the first half of 2026 compared to $2.1 million for the first half of 2025, reflecting the current vintage of clinical trials really reaching substantial completion. As Hermann pointed out, we are planning additional clinical developments for the coming years, aiming to expand the reach of our products, but depending on available funds. Net loss for the quarter was $0.6 million, or $0.05 per share, compared to a net loss of $5.3 million, or $0.57 per share, in 2025. For the first half, net loss was $5.4 million or $0.44 per share compared to $9.5 million or $1.05 per share.

Adjusted EBITDA for the quarter was negative $0.2 million compared with negative $5.1 million in the prior year quarter. An improvement of approximately $5 million and an adjusted EBITDA margin of negative 1.4% against negative 56.9% in 2025. For the first half, adjusted EBITDA was negative $3.7 million compared with negative $9.5 million last year. An adjusted EBITDA margin of negative 16.9% versus negative 54%.

Now turning to the balance sheet and liquidity, as of June 30, 2026, we had cash and cash equivalents of $4.7 million compared with $6.4 million at December 31, 2025. Operating cash used in the first half of 2026 was $1.7 million, down from $7.2 million a year ago.

The last figure also includes a $3.7 million one-time paydown of related party payables that were connected to the strategic transaction that happened in the first quarter of 2026. Including that item, changes in working capital were a net source of cash for the period. We continue to make progress towards cash flow breakeven in 2026. Total liabilities were $18.1 million, essentially unchanged from year end 2025. Our only outstanding indebtedness is $4.6 million of convertible notes maturing in November of 2027. We have no bank or term debt. Total shareholders' equity was $6.0 million compared with $10.5 million at December 31, 2025.

As we have disclosed in our filings, the company has included a going concern qualification in its financial statements. While we have demonstrated meaningful progress towards cash flow breakeven, and believe we will achieve that this year, and this quarter is the clearest evidence of that progress. Our current capital resources require us to continue expanding our commercial operations and controlling expenses. We plan to address this through the continued growth of Ameluz revenue, the realization of the next milestone payment of $1 million from the XEPI divestiture, and, if necessary, securing a working capital line of credit or similar facility when and if needed. With that overview of our results, we are now ready to take questions from our covering analysts. I'll hand it back to you, operator.

Operator

[Operator Instructions ] Our first question comes from Bruce Jackson with StoneX. Please go ahead.

질의응답

Bruce Jackson

And congratulations on the quarter. I wanted to start off with the basal cell carcinoma launch. So it's the same call point and it works with the existing lamp. Is there anything else that needs to be done in terms of like putting the reimbursement in place or getting the sales force trained? What are the other additional steps that need to be done prior to launch?

George Jones

I'll take that one. First of all, thanks for the question. The great thing about the sBCC indication is how perfectly it fits within our current call point and our current kind of strategic priorities. The actions that really need to be taken place to get ready for this launch are to finalize our marketing materials, pre-clear those with the FDA, and train our sales force, and then finalize our reimbursement strategy as well. But outside of those, we're ready to go and begin selling this and begin talking about it when it's approved.

Bruce Jackson

Okay. Okay. And then I wanted to follow up with the ITC commentary. So I believe there are two patents involved here, and you've successfully challenged one, the inter partes review. Is it possible to get the other patent reviewed? So can you like basically get this whole thing tossed out? That's the first part of the question. And if not, can you tell us more about the remediation plan and will this require a redesign of the lamp that would then have to go back through the FDA process?

Hermann Lubbert

Yes, I take that one. Thanks for asking, Bruce. Well, first to the process with the other patent. We cannot do this with the other patent. This other patent is basically identical to the first patent. And the answer would in all likelihood be the same. However, we can't attack that patent through the same mechanism because the current strategy of the director of the patent office is not to allow that strategy for patents which are already discussed in some kind of a court like the ITC. So for pure formalities, we cannot do that.

However, we can appeal the decision of the ITC. And that will be done for both patents. And at that point, we can bring the arguments for both patents together. Now, whether or not that is going to be successful is in the end not as relevant because of the workaround strategy that we are implementing currently. And this workaround strategy is based on very minor changes in the lamp. If you look at patents in a space where there isn't really much new in one of these lamps, I mean it's a 5-panel lamp and panels are connected by hinges. There were lamps like this out there everywhere.

So there's a certain component of hinge that Sun claims they invented. We obviously disagree, but the ITC has agreed with them. And we have to remove that component of the hinge to actually get beyond the space of those patents. So it's really a minor change that we're introducing into the lamps.

Bruce Jackson

And then that minor change, does it have to go through the FDA?

Hermann Lubbert

Yes, it has to go through the FDA in what's called a CBE-30 process. And we have applied for that. And FDA has agreed that this is the process. And from the FDA point of view, we already got permission to sell that.

Bruce Jackson

Okay, and then one last follow up. In terms of the product performance, is this the same as the one that's going to be.....

Hermann Lubbert

Sorry for interrupting. I should add for clarity that this is just the FDA perspective. And now the border control has to agree that this will also take us outside of the space of the ITC ruling. And that is what we are currently waiting for. So we could in principle sell from the FDA perspective, but in practice we cannot because we have to wait for that other step.

Bruce Jackson

Okay. And then last question for me, this feature change in the XL, will the customer notice any appreciable difference in performance?

Hermann Lubbert

No, for the time being the lamp will still continue to be used exactly in the same way in which it is approved currently by the FDA.

Operator

Our next question comes from Jonathan Aschoff with ROTH Capital Partners.

Jonathan Aschoff

It sounds like you have 243 XL lamps out there out of 101 total. Is that accurate? I'm sorry, out of 801 total. Is that accurate?

George Jones

Yes, that sounds about right.

Jonathan Aschoff

Okay. So, do any docs have both lamps and therefore they can order all the Ameluz they want and use it however they want? Why would they care?

George Jones

So the customers that have an XL in place, an XL alone in place, we no longer are selling them Ameluz for use with that infringing device. The people that bought Ameluz prior to the order going into effect, we are not encouraging them to use Ameluz with the infringing device, but they own the Ameluz and they own the device.

Jonathan Aschoff

Okay, I mean, what, is someone out there policing this to scare these guys?

George Jones

Could you repeat the question? You cut out there?

Jonathan Aschoff

I said, is someone out there policing this to scare these people into not using inventory?

George Jones

It is not their obligation. So it's the obligation of Biofrontera in this situation to not sell Ameluz after the order went into effect for use for the infringing device. But Ameluz that they own and a lamp that they own, they're free to use it as they see fit. So they're under no obligation not to use it, the offices that own it.

Jonathan Aschoff

And then in the future, you're not going to give them a newly designed lamp. You're not going to swap it out for free. You're going to sell it to them outright, yes?

George Jones

So the people that own, as Hermann mentioned, we're working on developing a non-infringing device. And the plan is once that non-infringing device is approved by the FDA, which Hermann mentioned is complete, and then also passes muster with the border control, border protection. The plan would be to work with those offices to replace their current lamp with a non-infringing device.

Jonathan Aschoff

Okay, so I guess I'm trying to understand, with 243 out of 801 being lamps for which you can't sell Ameluz, how does that maintain your annual sort of revenue expectations? It used to be guidance. Now it's just kind of an unwritten expectation. How is that possible?

George Jones

So, we were able to use the period from when the order was issued to when it went into effect to sell into those customers. And so, many of our customers who had an XL were able to buy in multiple months of inventory, to be able to continue to use Ameluz while we are working on creating a non-infringing device that Hermann mentioned. We also have other strategies to ensure that patients are taken care of within these offices.

Jonathan Aschoff

Okay, so they will use Ameluz with the infringing device for as long as they can, like I was alluding to earlier, which is what I would hope and expect. Correct?

George Jones

Yes, we cannot and will not encourage future use of the infringing device, but Ameluz that they purchased before the order went into effect can be used with the XL lamp, yes.

Operator

This concludes our question and answer session. I would like to turn the call back over to management for any closing remarks.

Hermann Lubbert

Yes, thank you, Operator, and thank you to everyone who joined us today. Let me leave you with three takeaways. First, the second quarter demonstrates the full impact of our transformed business model. Revenue is up 33%, gross margin is approximately 80%, and adjusted EBITDA within $200,000 of breakeven in a traditionally weak quarter. Second, our growth beyond 2026 is visible and concrete. We have a PDUFA date for superficial basal cell carcinoma on September 28 and expect the full launch in the first quarter of 2027, which if approved, would make Ameluz the first PDT in the United States approved for the treatment of cancerous tumors.

We are filing a supplemental NDA around the end of this quarter to expand the AK label to the extremities, neck, and trunk, and 240 square centimeters. Each of these label expansions flows through the installed lamp base and sales force we have already built.

And third, we are managing our two constraints, a cash position that requires discipline and an ITC matter that affects one of our lamps, which we are remediating and actively contesting. Neither changes the trajectory of this business nor our dedication to our customers or their patients. And in fact, continues to make Biofrontera more resilient.

I want to thank our entire team for their dedication and hard work. I also want to thank our shareholders, the healthcare professionals who use our products, and most importantly, the patients whose lives we are helping to improve in their fight against skin cancers. Thank you all for your continued support. Have a wonderful day.

Operator

The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.